Comparison of explanatory and pragmatic design choices in a cluster-randomized hypertension trial: effects on enrollment, participant characteristics, and adherence

Karen L Margolis, A Lauren Crain, Beverly B Green, Patrick J O'Connor, Leif I Solberg, MarySue Beran, Anna R Bergdall, Pamala A Pawloski, Jeanette Y Ziegenfuss, Meghan M JaKa, Deepika Appana, Rashmi Sharma, Amy J Kodet, Nicole K Trower, Daniel J Rehrauer, Zeke McKinney, Christine K Norton, Patricia Haugen, Jeffrey P Anderson, Benjamin F Crabtree, Sarah K Norman, JoAnn M Sperl-Hillen, Karen L Margolis, A Lauren Crain, Beverly B Green, Patrick J O'Connor, Leif I Solberg, MarySue Beran, Anna R Bergdall, Pamala A Pawloski, Jeanette Y Ziegenfuss, Meghan M JaKa, Deepika Appana, Rashmi Sharma, Amy J Kodet, Nicole K Trower, Daniel J Rehrauer, Zeke McKinney, Christine K Norton, Patricia Haugen, Jeffrey P Anderson, Benjamin F Crabtree, Sarah K Norman, JoAnn M Sperl-Hillen

Abstract

Background: Explanatory trials are designed to assess intervention efficacy under ideal conditions, while pragmatic trials are designed to assess whether research-proven interventions are effective in "real-world" settings without substantial research support.

Methods: We compared two trials (Hyperlink 1 and 3) that tested a pharmacist-led telehealth intervention in adults with uncontrolled hypertension. We applied PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) scores to describe differences in the way these studies were designed and enrolled study-eligible participants, and the effect of these differences on participant characteristics and adherence to study interventions.

Results: PRECIS-2 scores demonstrated that Hyperlink 1 was more explanatory and Hyperlink 3 more pragmatic. Recruitment for Hyperlink 1 was conducted by study staff, and 2.9% of potentially eligible patients enrolled. Enrollees were older, and more likely to be male and White than non-enrollees. Study staff scheduled the initial pharmacist visit and adherence to attending this visit was 98%. Conversely for Hyperlink 3, recruitment was conducted by clinic staff at routine encounters and 81% of eligible patients enrolled. Enrollees were younger, and less likely to be male and White than non-enrollees. Study staff did not assist with scheduling the initial pharmacist visit and adherence to attending this visit was only 27%. Compared to Hyperlink 1, patients in Hyperlink 3 were more likely to be female, and Asian or Black, had lower socioeconomic indicators, and were more likely to have comorbidities. Owing to a lower BP for eligibility in Hyperlink 1 (>140/90 mm Hg) than in Hyperlink 3 (>150/95 mm Hg), mean baseline BP was 148/85 mm Hg in Hyperlink 1 and 158/92 mm Hg in Hyperlink 3.

Conclusion: The pragmatic design features of Hyperlink 3 substantially increased enrollment of study-eligible patients and of those traditionally under-represented in clinical trials (women, minorities, and patients with less education and lower income), and demonstrated that identification and enrollment of a high proportion of study-eligible subjects could be done by usual primary care clinic staff. However, the trade-off was much lower adherence to the telehealth intervention than in Hyperlink 1, which is likely to reflect uptake under real-word conditions and substantially dilute intervention effect on BP.

Trial registration: The Hyperlink 1 study (NCT00781365) and the Hyperlink 3 study (NCT02996565) are registered at ClinicalTrials.gov.

Keywords: Hypertension; Pharmacist care; Pragmatic trials; Self-measured blood pressure; Telemonitoring.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
a (top) and b (bottom) PRECIS-2 wheels for Hyperlink 1 (a) and Hyperlink 3 (b)
Fig. 2
Fig. 2
Flow diagram of randomization, eligibility, enrollment, intervention, and follow-up in Hyperlink 1 and Hyperlink 3. Abbreviations: Medication therapy management (MTM), blood pressure (BP), usual care (UC), telemonitoring intervention (TI), clinic-based care (CBC), telehealth care (TC), primary care professional (PCP), medical assistant (MA), chronic kidney disease (CKD), systolic blood pressure (SBP)

References

    1. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. doi: 10.1136/bmj.h2147.
    1. Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, Owens DK, Goldstein MK. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44(7):646–657. doi: 10.1097/01.mlr.0000220260.30768.32.
    1. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182.
    1. Carter BL, Rogers M, Daly J, Zheng S, James PA. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169(19):1748–1755. doi: 10.1001/archinternmed.2009.316.
    1. Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens. 2012;14(1):51–65. doi: 10.1111/j.1751-7176.2011.00542.x.
    1. Dehmer SP, Baker-Goering MM, Maciosek MV, Hong Y, Kottke TE, Margolis KL, Will JC, Flottemesch TJ, LaFrance AB, Martinson BC, Thomas AJ, Roy K. Modeled health and economic impact of team-based care for hypertension. Am J Prev Med. 2016;50(5 Suppl 1):S34–S44. doi: 10.1016/j.amepre.2016.01.027.
    1. Community Preventive Services Task Force Team-based care to improve blood pressure control: recommendation of the Community Preventive Services Task Force. Am J Prev Med. 2014;47(1):100–102. doi: 10.1016/j.amepre.2014.03.003.
    1. Proia KK, Thota AB, Njie GJ, Finnie RK, Hopkins DP, Mukhtar Q, Pronk NP, Zeigler D, Kottke TE, Rask KJ, Lackland DT, Brooks JF, Braun LT, Cooksey T. Community Preventive Services Task F. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47(1):86–99. doi: 10.1016/j.amepre.2014.03.004.
    1. Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ. 2004;329(7458):145. doi: 10.1136/.
    1. Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010;42(5):371–386. doi: 10.3109/07853890.2010.489567.
    1. Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57(1):29–38. doi: 10.1161/HYPERTENSIONAHA.110.160911.
    1. Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am J Hypertens. 2015;28(10):1209–1221. doi: 10.1093/ajh/hpv008.
    1. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013;159(3):185–194. doi: 10.7326/0003-4819-159-3-201308060-00008.
    1. Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, Earle K, George J, Godwin M, Green BB, Hebert P, Hobbs FDR, Kantola I, Kerry SM, Leiva A, Magid DJ, Mant J, Margolis KL, McKinstry B, McLaughlin MA, Omboni S, Ogedegbe O, Parati G, Qamar N, Tabaei BP, Varis J, Verberk WJ, Wakefield BJ, McManus RJ. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):e1002389. doi: 10.1371/journal.pmed.1002389.
    1. Margolis KL, Kerby TJ, Asche SE, Bergdall AR, Maciosek MV, O’Connor PJ, Sperl-Hillen JM. Design and rationale for home blood pressure telemonitoring and case management to control hypertension (HyperLink): a cluster randomized trial. Contemp Clin Trials. 2012;33(4):794–803. doi: 10.1016/j.cct.2012.03.014.
    1. Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, Kerby TJ, Klotzle KJ, Maciosek MV, Michels RD, O’Connor PJ, Pritchard RA, Sekenski JL, Sperl-Hillen JM, Trower NK. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310(1):46–56. doi: 10.1001/jama.2013.6549.
    1. Margolis KL, Crain AL, Bergdall AR, Beran M, Anderson JP, Solberg LI, O’Connor PJ, Sperl-Hillen JM, Pawloski PA, Ziegenfuss JY, Rehrauer D, Norton C, Haugen P, Green BB, McKinney Z, Kodet A, Appana D, Sharma R, Trower NK, Williams R, Crabtree BF. Design of a pragmatic cluster-randomized trial comparing telehealth care and best practice clinic-based care for uncontrolled high blood pressure. Contemp Clin Trials. 2020;92:105939. doi: 10.1016/j.cct.2020.105939.
    1. 2021 Quality Rating System Measure Technical Specifications. September 2020; . Accessed 1 June 2021.
    1. Controlling High Blood Pressure. November 2019; . Accessed 1 June 2021.
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572. doi: 10.1001/jama.289.19.2560.
    1. Schwartz G, Kerandi H, Luehr D, O’Connor PJ, Margolis KL, Reddy G, et al. Hypertension diagnosis and treatment (Healthcare guideline) Minneapolis: Institute for Clinical Systems Improvement; 2010.
    1. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Sr, Williamson JD, Wright JT., Jr 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–1324. doi: 10.1161/HYP.0000000000000066.
    1. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron HEM-907 device for blood pressure measurement. Blood Press Monit. 2002;7(4):237–241. doi: 10.1097/00126097-200208000-00006.
    1. Beran M, Asche SE, Bergdall AR, Crabtree B, Green BB, Groen SE, Klotzle KJ, Michels RD, Nyboer RA, O’Connor PJ, Pawloski PA, Rehrauer DJ, Sperl-Hillen JM, Trower NK, Margolis KL. Key components of success in a randomized trial of blood pressure telemonitoring with medication therapy management pharmacists. J Am Pharm Assoc (2003) 2018;58(6):614–621. doi: 10.1016/j.japh.2018.07.001.
    1. Kerby TJ, Asche SE, Maciosek MV, O’Connor PJ, Sperl-Hillen JM, Margolis KL. Adherence to blood pressure telemonitoring in a cluster-randomized clinical trial. J Clin Hypertens (Greenwich) 2012;14(10):668–674. doi: 10.1111/j.1751-7176.2012.00685.x.
    1. Johnson KE, Neta G, Dember LM, Coronado GD, Suls J, Chambers DA, Rundell S, Smith DH, Liu B, Taplin S, Stoney CM, Farrell MM, Glasgow RE. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. Trials. 2016;17:32. doi: 10.1186/s13063-016-1158-y.
    1. Glasgow RE, Gaglio B, Bennett G, Jerome GJ, Yeh HC, Sarwer DB, Appel L, Colditz G, Wadden TA, Wells B. Applying the PRECIS criteria to describe three effectiveness trials of weight loss in obese patients with comorbid conditions. Health Serv Res. 2012;47(3 Pt 1):1051–1067. doi: 10.1111/j.1475-6773.2011.01347.x.
    1. Dember LM, Lacson E, Jr, Brunelli SM, Hsu JY, Cheung AK, Daugirdas JT, Greene T, Kovesdy CP, Miskulin DC, Thadhani RI, Winkelmayer WC, Ellenberg SS, Cifelli D, Madigan R, Young A, Angeletti M, Wingard RL, Kahn C, Nissenson AR, Maddux FW, Abbott KC, Landis JR. The TiME Trial: a fully embedded, cluster-randomized, pragmatic trial of hemodialysis session duration. J Am Soc Nephrol. 2019;30(5):890–903. doi: 10.1681/ASN.2018090945.
    1. Green BB, Vollmer WM, Keast E, Petrik AF, Coronado GD. Challenges in assessing population reach in a pragmatic trial. Prev Med Rep. 2019;15:100910. doi: 10.1016/j.pmedr.2019.100910.
    1. Mitchell SL, Volandes AE, Gutman R, Gozalo PL, Ogarek JA, Loomer L, McCreedy EM, Zhai R, Mor V. Advance care planning video intervention among long-stay nursing home residents: a pragmatic cluster randomized clinical trial. JAMA Intern Med. 2020;180(8):1070–1078. doi: 10.1001/jamainternmed.2020.2366.
    1. Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Maciosek MV, Nyboer RA, O’Connor PJ, Pawloski PA, Sperl-Hillen JM, Trower NK, Tucker AD, Green BB. A successful multifaceted trial to improve hypertension control in primary care: why did it work? J Gen Intern Med. 2015;30(11):1665–1672. doi: 10.1007/s11606-015-3355-x.
    1. Hernan MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377(14):1391–1398. doi: 10.1056/NEJMsm1605385.

Source: PubMed

3
Sottoscrivi